Depression in the context of medical disorders: New Pharmacological pathways revisited

5Citations
Citations of this article
119Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The depressive state has been characterised as one of elevated inflammation, changed cardiovascular parameters and a deranged metabolic situation all of which holds promise for a better understanding and handling of treatment-resistance in affective disorders as well as for future developments in treatment algorithms. In this context several biomarkers are differentially regulated by antidepressant treatment and connected to metabolic, inflammatory, cardiovascular and apoptotic components of the pathophysiology, i.e. adiponectin, apolipoprotein-B, B-Type natriuretic peptide, cortisol, CRP, cysteine, homocysteine, fibrinogen, adiponectin, BMI, glycated hemoglobin A1c, leptin, interferon-gamma, high-density lipoprotein, interleukin interleukin-1alpha, -1beta, -2, -4, -5, -6, -8, -10, -12, -13, -17, insulin-like growth factor-1, low-density lipoprotein, myeloperoxidase, osteoprotegerin, tumour necrosis factor alpha, troponins, triglycerides etc. In this context antidepressants exert different modulatory effects on the outcome, incidence and mortality concerning several severe disorders, i.e. cancer, diabetes, stroke, inflammation, stroke and cardiovascular risk. Vice versa different drugs used in the treatment of these disorders have a favourable effect in depressive states, e.g. statins, aspirine, NSAIDs, pioglitazone, celecoxib, peroxisome proliferator-Activated receptor-gamma agonists and minocycline. In this review, actions of different antidepressant treatment strategies on cancer, stroke, diabetes and cardiovascular disorders are shown and the influence on the outcome of the disorders is differentially discussed. In conclusion a hypothetic model for the implication of actual findings in everyday clinical practice is proposed. In this context personalized treatment could be used to tailor treatment to specific individuals according to their clinical endophenotypes. Moreover a potential target for the development of novel intervention strategies might be used.

References Powered by Scopus

The role of inflammation in depression: From evolutionary imperative to modern treatment target

2503Citations
N/AReaders
Get full text

Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects a systematic review and meta-analysis of randomized clinical trials

773Citations
N/AReaders
Get full text

A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)

492Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Prebiotics may reduce serum concentrations of C-reactive protein and ghrelin in overweight and obese adults: A systematic review and meta-Analysis

36Citations
N/AReaders
Get full text

Inflammation and remission in older patients with depression treated with electroconvulsive therapy; findings from the MODECT study<sup>✰</sup>

31Citations
N/AReaders
Get full text

Whole-body cryotherapy – promising add-on treatment of depressive disorders

11Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Lang, U. E., & Walter, M. (2018, January 1). Depression in the context of medical disorders: New Pharmacological pathways revisited. NeuroSignals. S. Karger AG. https://doi.org/10.1159/000482001

Readers over time

‘17‘18‘19‘20‘21‘22‘23‘24‘25010203040

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 37

73%

Researcher 9

18%

Lecturer / Post doc 3

6%

Professor / Associate Prof. 2

4%

Readers' Discipline

Tooltip

Medicine and Dentistry 35

59%

Psychology 11

19%

Nursing and Health Professions 7

12%

Pharmacology, Toxicology and Pharmaceut... 6

10%

Save time finding and organizing research with Mendeley

Sign up for free
0